PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4: C07K 15/00, C12P 21/00	•
C12N 5/00, G01N 33/569, 33/577	
C07K 3/18 // C12N 15/00	
(C12P 21/00, C12R 1:91)	

(11) International Publication Number:

WO 86/ 04336

(43) International Publication Date:

31 July 1986 (31.07.86)

(21) International Application Number:

PCT/EP86/00018

A1

(22) International Filing Date:

21 January 1986 (21.01.86)

(31) Priority Application Number:

8501473

(32) Priority Date:

21 January 1985 (21.01.85)

(33) Priority Country:

- (71) Applicants: INSTITUT PASTEUR [FR/FR]; 25-28, rue du Dr. Roux, F-75724 Paris Cedex 15 (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTI-FIQUE [FR/FR]; 15, quai Anatole France, F-75008 Paris (FR).
- (72) Inventors: CHASSAGNE, Jacques; 3, rue de Leyrat, F-63670 Le Cendre (FR). VERRELLE, Pierre; Rue Guyot-Dessaigne, F-63730 Plauzat (FR). KLATZ-MANN, David; 84, quai de Jemmapes, F-75010 Paris (FR). MONTAGNIER, Luc; 21, rue de Malabry, F-92350 Le Plessis Robinson (FR). DIONET, Claude;

27, La Rivière, F-63670 Le Cendre (FR), GLUCK-MAN, Jean-Claude; 70, bld. de Port Royal, F-75005 Paris (FR).

- (74) Agents: GUTMANN, Ernest et al.; 67, bd. Haussmann, F-75008 Paris (FR).
- (81) Designated States: AT (European patent), AU, BE (European patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FR (European patent), CM (OAPI patent), DE (European patent), DK, FR (European patent) GA (OAPI patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent).

Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MONOCLONAL ANTIBODIES AGAINST CORE PROTEINS OF LYMPHADENOPATHY-ASSOCIAT-**ED-VIRUSES**

(57) Abstract

Monoclonal antibodies which recognize core proteins of lymphadenopathy-associated-viruses (LAV) and the hybridomas which secrete them. Monoclonal antibodies which recognize LAV p13, p18, p25 and p55 proteins are disclosed. Said monoclonal antibodies are useful in detecting the corresponding proteins or polypeptides in mixtures which contain them. When said antibodies are immobilized on an insoluble support, they can be used for the purification of the corresponding polypeptides from mixtures which contain them.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

ΑT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark	MC	Monaco	US	United States of America
FI	Finland	MG	Madagascar		
FR	France	ML	Mali		

Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses.

The invention relates to monoclonal antibodies which recognize polypeptides, whether glycosylated or not, encoded by genomic RNA of lymphadenopathy-associated virus (LAV), or cloned DNA derived therefore, to the hyridomas secreting said antibodies and to a process for their preparation and finally to their uses.

A method for cloning such DNA sequences has already been disclosed in British Patent Application Nr. 84 23659 filed on September 19, 1984, in the European Patent Application Nr. 85 401799 filed on September 17, 1985 and in the International Patent Application PCT/EP/85 00487 filed on September 18, 1985. Reference is hereafter also made to these applications as concerns subject matter in common with the further improvements to the invention disclosed herein.

The present application will also refer herein to the contents of the International application filed on October 18, 1985 PCT/EP 85 00548 on behalf of INSTITUT PASTEUR and the CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. It is understood that the contents of the two preceding applications are entirely incorporated herein by reference.

More particularly the molecular cloning of both cDNA and integrated proviral forms of LAV have been reported. The recombinant phage clones were isolated from a genomic library of LAV-infected human T-lymphocytes DNA partially digested by HindIII. The insert of recombinant phage λJ 19 was generated by HindIII cleavage within the R element of the long terminal repeat (LTR). Thus each extremity of the insert contains one part of the LTR. The

- X(.

possibility of clustered HindIII sites within R has been eliminated by sequencing part of a LAV cDNA clone, pLAV 75, corresponding to this region. Thus the total sequence information of the LAV genome can be derivated from the 5 AJ19 clone.

Using the M13 "shotgun" cloning and dideoxy chain termination method (Sanger et al., 1977), the nucleotide sequence of the λ J19 insert has been determined. The reconstructed viral genome with two copies of the R sequence is 9193 nucleotides long. The numbering system starts at the cap site of virion RNA. The entire sequence is shown in figs 1a-1e of the International application, also enclosed herewith.

The present invention aims at providing for the 15 more accurate identification of significant LAV proteins or glycoproteins and also at providing monoclonal antibodies against proteins and polypeptides carrying significant immunogenic sites or epitopes of the LAV virus proteins or glycoproteins.

The invention is more particularly concerned with monoclonal antibodies which recognize LAV core proteins or fragments thereof, particularly the p13, p18, p 25 and p55 proteins.

The invention is thus more particularly concerned 25 with and relates to monoclonal antibodies which recognize respectively:

- a p55 protein deemed to be encoded by the DNA sequence, extending from about nucleotide 336 up to about nucleotide 1650 of the LAVcDNA, which p55 protein is considered to
 30 contain aminoacid sequences corresponding to those of the core proteins p18 and p25 of the LAV virus;
 - a p25 protein, deemed to be encoded by the DNA sequence, extending from about nucleotide 732 up to about nucleotide 1300 of LAVcDNA;

- a p13 protein, deemed to be encoded by the DNA sequence, extending from about nucleotide 1371 to about nucleotide 1650;

- a p18 protein, deemed to be encoded by the DNA sequence,
5 extending from about nucleotide 336 up to about nucleotide
611.

More particularly the invention relates to monoclonal antibodies recognizing polypeptides having peptidic sequences identical or equivalent to those encoded by the 10 DNA sequences extending approximately between the following nucleotide positions:

- 336 to 1650 (p55)
- 336 to 611 (p18)
- 1371 to 1650 (p13)
- 15 656 to 1300 (p25).

It should be mentioned that the p13, p18 and p25 all appear to derive from a same precursor, i.e. p55.

More particularly the invention concerns the monoclonal antibodies produced by the hybridomas deposited on October 24, 1984 at the "Collection Nationale des Cultures de Micro-organismes" or, under the abbreviated form "CNCM", under the numbers which follow:

LAV-A1 (p18) n° I-355

LAV-B1 (p25) n° I-356

25 LAV-C1 (p25) n° I-357

LAV-D1 (membrane) .. n° I-358

LAV-E1 (p25) n° I-359

LAV-F1 (p13) n° I-360.

The designations used for identifying the hybri30 domas correspond to the purified peptides obtained by
standard purification procedures starting from lysates of
LAV virus, which peptides were initially used for
immunizing the animals from which the splenic cells used
for the production of the corresponding hybridomas were

4

obtained. Purified peptides for use in the production of said monoclonal antibodies can also be obtained by immunizing animals with the corresponding purified expression products of the DNA recombinants disclosed in the abovementioned PCT application and European application. The general procedure for making said hybridomas will be described later.

A general procedure used for the production of each of the above said monoclonal antibodies will be 10 described hereafter.

Immunisation of mice

Groupes of 6-8 week old Balb/c mice were used. The different groups received the different proteins mentioned hereabove respectively. The immunization protocols, identical in all groups, comprised injections three times by the intraperitoneal route, then once by the intravenous route, each time of 10 µg of the antigenic preparation in the presence of Freund complete adjuvant at day 0, and of incomplete Freund adjuvant at day 14 without adjuvant at days 28 and 42.

Fusion and culture of the hybrids

the azaguanine-resistant and non secretor variant 6.53 of myeloma P3 X 63 Ag8, which itself originated from the MPOC-21 cell line was used. The fusion with the splenocytes of the immunized mice was performed in the presence of polyethylene-glycol 4000, according to the technique of FASEKAS DE ST-GROTH and SCHEIDEGGER at day 45. The selection of the hybrides in RPMI 16-40 "HAT" medium was carried out according to the same culture technique in plates comprising 24 wells (Costar).

The hybridomas which produced the specific antibodies were then cloned in plates comprising 96 wells respectively, in the presence of a feeder layer of syngenic thymocytes. The secreting clones selected were then

5

expanded in plates comprising 24 wells respectively, still in the presence of thymocytes. When confluence appeared in one of the wells, the clone was intraperitoneally injected to BALB/c mice which had received 8 days earlier an injection of Pristane and/or maintained in liquid culture.

Detection of the anti-LAV antibodies

Five different techniques have permitted the characterisation of clones producing the antibodies of desired specificity. In a first step, the hybrids secreting the desired antibodies were detected by an ELISA assay that revealed the mice immunoglobulins in the supernatant. Starting from this first selection, the supernatants which contained antibodies oriented against the viral constituents sought were screened by means of an ELISA assay or by an immunogluorescence assay on human cells that produced the virus. Finally the supernatants were analyzed by radio-immunoprecipitation of virus labelled with 35 scysteine and by the Western-Blot technique on a viral preparation whereby the specificities of the anti-LAV antibodies were determined.

RESULTS

The cells obtained, starting from different fusions were then cultivated in 648 wells. The microscopic examination has shown that most of these wells contained a single hybrid clone capable of growing in the "HAT" selective medium. More than 50 % of the clones produced antibodies that provided a positive response in the antivirus ELISA assay. The most representative fusions were tested by the Western-Blot technique and several hybridomas of each group were sub-cloned, taking into account their specificity, their reactivity in the antivirus ELISA assay and their development rate in cultures. Hybrids were retained which produced antibodies which recognized more specifically the proteins or polypeptides which had been

used initially for immunizing the mice. All sub-clones obtained were shown to secrete antibodies which after expression, were injected in syngenic mice. The analysis of antibody specificities in the different ascites liquids obtained confirmed the specificities of the antibodies formed in each of the ascites with respect to the corresponding proteins.

The hybridomas which have been deposited at the CNCM and which were identified above are representative of the hybridomas that can be obtained using the above proteins. They form part of the invention too.

The monoclonal antibodies obtained can themselves be brought into play for purifying porteins or polypeptides which have in common an antigenic site with the 15 proteins initially used for producing the hybridomas. The invention thus also relates to the purification processes per se. Such processes are advantageously used for the treatment of lysates of LAV, of infected T lymphocytes or of any other cells capable of producing LAV or an 20 analogous virus. This process can also be applied to the identification of the proteins produced by cells which have been genetically engineered with recombinant DNAs as defined above and containing a DNA sequence encoding the relevant epitope. The monoclonal antibodies used in said 25 process are advantageously immobilized on a solid support, for instance one suitable for affinity chromatography operations, such as a tri-dimensional cross-linked agarose lattice, commercialized under the trademark SEPHAROSE by the Swedish Company PHARMACIA A.G., for instance by the cyanogene bromide method.

The process of the invention thus comprises the step including contacting the solution containing said polypeptide with an affinity column carrying said monoclonal antibodies in order to selectively retain said

polypeptides, then recovering the polypeptide upon dissociation of the antigen-antibody complex by means of an appropriate buffer, for instance a salt solution of appropriate ionic strength, for instance at pH 2-4. A suitable 5 salt for constituting such buffers is formed of ammonium acetate.

Having isolated such polypeptide it will immediately appear that the same monoclonal antibodies can be further used for the study fo fragments obtained from the corresponding polypeptide likely to contain the relevant epitope, said fragments having been obtained from the larger polypeptide, for instance by cleavage of the latter enzymes capable of fragmenting polypeptides proteins. By way of examples of such enzymes, one may mention the enzyme of Staphylococcus aureus V 8, alphachymotrypsin, the mouse sub-maxillary gland protease commercialized by the BOEHRINGER Company, the collagenase Vibrio alginolyticus chemovar iophagus, which recognizes specifically Gly-Pro and Gly-Ala dipeptides, etc...

the monoclonal antibody produced by the hybridoma deposited at the CNCM under Nr. I-355 is of particular significance. More particularly the monoclonal antibodies recognize both p18 and p55. Consequently it follows that the epitope more significantly recognized by said antibody 25 remains unmodified when p55 (precursor of p18 and p25) is cleaved into its different components.

Thus this antibody is of particular interest for purifying both p18 and p55. The other components included in p55, particularly p25 can then be purified starting from the purified p55. It has been further found that said antibody is capable of recognizing the LAV virus in compositions containing same. It can be hypothesized that p18 behaves accordingly as a transmembranous protein, which is at least particularly exposed through the virus envelope

and which is further expressed by the cells.

This antibody is thus of particular interest for - the detection of viral particles in a biological sample, particularly a serum obtained from patients to be diagnosed for AIDS or LAS,

- the detection of infected lymphocytes,
- the detection in a biological sample as mentioned above or in a culture of infected lymphocytes,
- the treatment by the antibody of cells which express the 10 virus.

The invention further relates

- to any other monoclonal antibody which recognizes any of the epitopes more specifically recognized by the monoclonal antibodies secreted by the hybridomas which have been deposited at the CNCM and, accordingly,
- to the hybridomas which secrete said other monoclonal antibodies.

20

25

CLAIMS

- 1 Monoclonal antibodies which recognize a core protein of the lymphadenopathy associated-virus (LAV).
- 2 The monoclonal antibodies of claim 1 which5 recognize a p13 protein of LAV.
 - 3 The monoclonal antibodies of claim 1 which recognize a p18 protein of LAV.
 - 4 The monoclonal antibodies of claim 1 which recognize a p25 protein of LAV.
- 10 5 The monoclonal antibodies of claim 1 which recognize a p55 protein of LAV.
 - 6 The monoclonal antibodies of claim 1 which recognize both a p13 protein and a p25 protein of LAV.
- 7 A monoclonal antibody according to claim 1
 15 selected from the group of the monoclonal antibodies which
 are secreted by the hybridomas deposited at the CNCM under
 numbers I-355, I-356, I-357, I-358, I-359 and I-360 or any
 monoclonal antibody recognizing the same epitope as that
 recognized by a monoclonal antibody produced by any of the
 20 above-mentioned hybromas.
 - 8 The hybridomas which secrete the monoclonal antibodies of any of claims 1 to 7.
 - 9 The use of a monoclonal antibody according to any of claims 1 to 7 for the in in vitro detection of the corresponding polypeptides in a biological sample or of the corresponding expression products on LAV-infected lymphocytes.
- 10 A method for the purification of a polypeptide contained in solubilized form in a biological sample,
 30 which polypeptide contains an epitope recognized by one of the monoclonal antibodies according to any of claims 1 to 7, wherein said method comprises contacting said biological medium with the corresponding monoclonal antibody affixed to or immobilized on an insolubilized support for

causing the fixation of said polypeptide on said immobilized monoclonal antibody, whereby a polypeptide-antibody complex is formed, separating the non fixed polypeptides and recovering said fixed antibody by the dissociation of said polypeptide-antibody complex.

GAG - LeudlaGludladrgdrgdrgClubleEslydladrgdlagerValLeuSer

gtgact cygatactagagat ccct cagac cctt ttagt cagtgtggaaat ct ctag cagtg cccc caacag ggact tgaaag cgaaag ccagag gag ct ct ct cgacg cag

GIYGIYGIULeudepatgttpgiulyeileatgleuatgftogiygiylyelyelyeltyehielievaittpaissetatgiuleugiuatgfhealevaitattogiy Gegegegagaattagategatggcaaaaaatteggttaaggccagggggaagaaaaaatataaattaaaagatagtatggggagggagggaggtteggagttaategtg

MetThrasadenProProlleProValGlyGluIlaTyrLysArgTrplleIleLeuGlyLeuAsnLysIleValArgHetTyrSerProThrSerIleLeuAspIleArgGlaGlyPro CyalyaThrII aleulyaAlalauGlyProAlaAlaThrlauGluGluHetHetThrAlaCyaGlnGlyValGlyGlyProGlyHialyaAlaArgValleuAlaGluAlaMetSerGln Gladen Tydrollevel Gladen Ilegingi yginnet Val Hiscialisiser Prodre Thr Leuden Ale Trp Val Lyeval Val Gludlyedis Phe Ser Prodluvel Ile ProMettheserale LeuSerglucjy ale Thr ProGlade pLeuden Thr Het Leuden Thr Vel Glydly Hie Gladle Ale Met Glamet Leulye Glu Thr II eden Gludla AlaGluTrpAapArgValWiaProValHiaAlaGlyProllaAlaProGlyGlnMetArgGluProArgGlyBerAspIlaAlaGlyThrThrBerThrLeuGluGluGluIlaGlyTrp LysGiuProPhadrgdapTyrValdapdrgPheTyrLyaThrLeudrgdlaGluGladlaSerGlnGluValLysdanTrpHetThrGluThrLeuLeuValGladsadladsaProdsp ValThrAsnSeralaThrIleMetMatGluArgGlyAsnPheArgAsnGluArgLyaIleValLyaCyaPheAsnCysGlyLysGluGlyHisIleAlaArgAsnCysArgAlaProArg LepLeuGluThrSerGluGlyCyeArgGlnIleLeuGlyGlnLeuGlnProSerLeuGlnThrGlySerGluGluLeuArgSerLeuTyrAenThrVelAleThrLeuTyrCyeValHie Gladrg IleGluIleLysdspThrLysGlud, aLeudspLysIleGluGluGluGluGladenLysSerLysLysdlaGlnGlnAladlaAladapThrGlyHisSerSerGlnValSe aagtaacaaattcagctaccataatcatacaaaggcaattttagcaaggcaaatgtaagattgttaagtgtttcaattgtgccaaaggcccagtagccagaaattccaggccccta gcctottagajacatcagascctotagacajatactgggacagctacaaccetcagacaggatcagakajacttagátcattatátatacagtagcaaccctctatgtgtg atcalacgatagacatalah gacaccalggalactitegacalcalagaccalargaccalan calargalak galargacacagcagcagcagacacacagcagcca gccalattaccctatactccacalacatccaccccalatcctacatcacccatatcacctacaactttaaatccatgcgtaaagtactacaaggctttcacccacaggctg ctecacatteccatecatecactecatecaccectattecaceceacateacheaceaatacaaceas ggatgacaaataatccacctatcccagtaggacaaatttätaäaagitggataatcctgggättaaataātaataagāatgtggcgtaggaggattctggacataagācaaggāg 1400 901

BerclucinthrårgaladenserprothrårgargciuleucinvaltrpciyargaepaendenteuserciudiaciyaladepargcinciytrvalserphedenPhePro CinserargprociuprothralaproprociuciuserphedrgserciyvalciuthrthrfhrprosercintyacinProtiedeplyaciuleutyrProleuthrSerLeu GiniieThrLeuTrpGinArgProLeuValThrIieLysIieGiyGiyGinLeuLysGiuAisLeuLeuAspThrGiyAisAapAapThrVaiLeuGiuGiuHetSerLeuProGiyArg

LyalyadiyCyaTrpLyaCyaGiyLyaGiuGiyHiaGinMatLyaAapCyaThrGiuArgGinAiaAanPheLeuGiyLyaIieTrpProSerTyrLyaGiyArgProGiyAanPheLeu

ggaaaagggg<mark>ett</mark>ggaaatgtagaaaggacaacaaatgaaagattgtagtagagacagggtaatttttaggaagatgtggcgttgctacaagggaaggggagttttt

1600

POL - PhetheArgGluAspLeuAlatheLeuGinGlyLysAlsArgGluPheter

tcagatcactetttggclacgaccctcaclataagatagggggggaactaaaggtggttattagatacaggaggacatgatacagtattagaagaaatgagtttgccaggaag Arg Ser LeuPheGlyAsnAspProSer SerGln

TrpLyeProly HeilieGlyClyIleGlyClyPhelleLyeValArgClnTyrAspClnIleLeuIleGluIleCysClyllaLysAlaIleClyClyThrValLeuValGlyFroThrFro 2000

ValAsnIleIleGlyArgAenLeuIeuThrGlnIleGlyGyeThrLeuAenPheProIleSerProIleGluThrValProValLyeLeuLysProGlyMetAspGlyProLyaValLys igtgaacataattggaagaaatcigitgaactcagattggttgcactttaaattttcccattagtcctattgaaactgtaccagtaaaattaaagccaggatggctggaaa

GintrpfroLeuThrGluGluLyelleLyeAlaLeuVelGlulleCysThrGluMetGluLyeGluGlyLyeIleSerLyelleGlyProGluAsaProTyrAsaThrProVelPheAla 2100

acatigoccattgacagaagaaaaaaaacattagtagaaatttgtacagaaatggaaaagggaagggaaatttcaaaaattgggcctgaaaatccatácaatactgcagtatttgg

IIelyelyelyekepSetThrlyeTtpArglyeleuVelAepPheArgGluleuAenLyeArgThrGlnAepPheTrpGluVelGlnleuGlyIIeProbleProAleGlyLeuLyeLye CatAAACAAAAAACACAGTACTAAATGGGGAAAATTAGTAGATTTCAGAGGAACTTAATAAGAGAACTCAAGACTTGGGAAGTTCAATTAGGAATACGAGATGCGGGGGGTTAAAAA

LysLysSorValThrValLeudspValGlydspAlaTyrPheSerValProLeudspGludspPheArgLysTyrThrAlePheThrIleProSerIledsaAsaGluThrProGlylle gaáaaateagtaacagtactggatggggtgatgcatáttttcagttcccttagatgaacattcaggaágtátactgcatttaccatacctagtataaacaatgacagggat

ArgTyrGlnTyrAenValleuProGlnGlyTrpLyeGlySerProAlallePheGlnSerSerHetThrLyelleLeuGluProPheArgLyeGlnAenFroAsplleValIleTyrGln 2600

TyrHetAspAspLeuTyrValGlySerAspLeuGluIlaGlyGlnHiaArgThrLysIlaGluGluLeuArgGlnHisLeuLeuArgTrpGlyLeuThrThrProAspLysLiaGln nt acat ggatgattt gtat gegatgt gagata gagaga ggat agaacaaaa kaga ggaggt gagagaa tot gttgag gegggattaggaggagagaaaaaaa 2700

Leudis Gludenar g Glulle Leulys Glupro Val Bis Gly Val Tyr Tyr Asppro Ser Lys Aspleu II a Ala Gluile Gin Lys Gin Gly Gin Gly Gin Trp Thr Tyr Gin II e Tyr

GinglupropheLysAsnLsuLysThrGlyLysTyrAlsArgThrArgGlyAlsHisThrAsnAspValLysGlnLeuThrGluAlsValGlnLysIlsThrThrGluSerIlsValIls TrpGlyLyaThrProLyaPhaLyaLauProllaGluLyaGluThrTrpGluThrTrpTrpTrpThrGluTyrTrpGlnAlaThrTrpllaProGluTrpGluPhaValAanThrProProLau atgeggaaagactectaaatttaaactacccatacaaaaggaaacatgcggaaacatgctggacagactattggcaaggcacctggattcctgagtgcgatttgtcaatacccctcttt

ArgGlnLyeValValThrLauThrAspThrThrAsnGlnLysThrGluLauGlnAlsII ellisLauAlsLauGlnAspBarGlyLauGluValAenII aValThrAspBerGlnTyrAls aagacaaaaaggaccetaactaacaacaaacaaacaagactgagttacaagcaattcatctagctttgcaggattcgggattagaagtaaatatagtaacaactcacaatatgg

acy acaccititacaccataacatatcaaccy citacacatitic ctaccit cocyccat cocytacccaacata to tatacaaactitatc ccaa tactic cataataagaattotocaacaactgoctgittatocaatttgoctotogacatagcagaatagocgitactcaacagaggggaagaaaatggagocagtagatoctagactag accopcalacatocacalady actalactecal tectacact tectal tectal tecand of the controcal contectation tales and a co

Ala Ser AspPhe AsnLau Pro Pro Val Ala Lys Glu Ila Val Ala Ber Cys Asp Lys Cys Gln Leu Lys Glu Ala Mat Wis Gly Gln Val Asp Cys Ser Pro Gly Ila Trp Glo

scctabteatittaacticcacctgtagtaccaaaaatagtaggcagctgtgataaatgtcagctaaaaggagaaggcatgcaccaagtagactgtagtcaggaatatgoca

3900

Olyclydebolbglayeldepyelevyelbetaleclylleatglysyellevydepolytleaeplyealecludepolyeathepyetyeglebetyetythesettpathemet Pocaccaaatcaacaactacataattagtcactcccaaatcacaaactatttttacatccaataaatagccccaacatcaacatcacaataatcacactactccacacta

LeuGlyllelleGlnAlaGlnProAspLyeSerGluSerGluLeuValAsnGlnIleIlaGluGlnLeuIleLysLysGluLyaValTyrLeuAlaTrpValProAlaHisLysGlyIle

IITA CGAATCATTCAA CCACCACCAGATAAAA GTGAATCAGAGTTA GTCAAA TAATAAG GCA GTTAATAAAAAA GGAAAAGGTGTATG GCCA TGGGTACCAGCAGCAGCAAT

3/. ORF OF Cyscladlu Ciulyscinārgserleuciyli effetciuārdagtapcinārihet II evel tapcināriahetārg II eārgtatīplysserleuvai Lysbismet Tyrval Ser Aacaaaacaaacattataccaattātīcaaaaacaattocatotattototocaagtacagggatgagggattagaggattagaaaagttātagtaaaagaggatātīt GlyLyaklaArgGlyTrpPheTyrArgHloHisTyrGluSerProHisProArgIleSerSerGluValHisIleProLeuGlyAspAlaArgLeuValIleThrThrTrpGlyLeu MisthrelycludrgdsptrpMisLauclyclnclyValSarllecluTrpArgLysLysArgTyrBarThrclnValAspProcluLaudlaAspClnLauIlaMisLauTyrTyrPha Leudep Cyether Hieleugiugiy Lyeveliieleuvelaievel Hievel Hievel Ciytyetiegiuureliiepen adiuthegiygingiutherietyepen Leuleu Actacattotacacatttacaacgaaaacttatoctoctacacttcatotaggaaggaatatatagaaggaaagttattocaggaaaagaggaaggaaaaggaaaagga Phedrevallyrfyrdredopferdredopfroleufrplysclyfrodlalysleuleufrplysclyclyclydlafalvallacindspdanserdspllelysvalfalfrodre AspCysPhoBorAspBorAleIleArgLysAlaLouLouGlyHisIleValSorProArgCysGluTyrGlaAlaGlyHisAsnLysValGlySorLouGlnTyrLouAlaLouAlaAl Nie den Phe Lys Arg Lys Gly Cly Ile Gly Cly Tyr Ber Als Gly Cludrg Ile Valda Ile Ile Als Thr Asp Ile Gla Thr Lys Glu Leu Gla Lys Gla Ile Thr Lys Ile Gla Asa LeullathrProLysLysllaLysProProLeuProSarValthrLysLeuthrGludspårgTrpåsnLysProClnLysThrLysGlyHisArgGlyBerHisThrMetAenGlyHi Tyrasprocinsercinci yvai valciusermataanlysciuleulyelyetietieciycinvalargaspcinalaciudieleulyathralavaicinmatalavaithetie TOCATACA GOLGADA GOLGA TOTO GOLGA GO GOLGA TO GOLGA A TOGO GOLGA GOLGA GOLGA GOLGA GOLGA GOLGA GOLGA GOLGA TOGO GOLGA TOGO GOLGA TOGO GOLGA GOLG tteactetttteaeactetectataaeaalgeecttattagacatatagcectaggtegatatataacagagacataacaaggtaggatgttocaatagctegcag cattaltalcaccialalícattaloccacctiticoctacictiticacalactracacacatroàticaarcaágcoccarágaccalgegoccacagegocacacatgaticaég ctacla tececalactela cacateta tela tela algaat ta a a cacata de a como como de a como como de a como como de a ccaccattitaáaagáááacccccatticocccotácagtccagcccaaagáatagtagacataatagcaacagacatacaaagtaáagaattacaaaattacaaaa 4300 ArglysalslysiigiisArgaspfyrdiyLysGinMetaleGiyAspAspGysValAlaBerArgGluAsp . 5000 4000

ENV - Lysclucialysta

4 ProdenProgingiuvalvaldenvaldenvalthrgiudenPhedenvartrpLysdendepHervalgiuginketHisgiudepIleIleSerLeuTrpdepGluBerLeuLysPro CCCAACCCAACAAAGTAGTAATGTGAAATGTGACAGAAATTTTAACATGTGGAAAAATGACATGGTAGAAACAGATGGATAATCAGTTTATGGGATCAAAGCCTAAAGCCA II e Lysdan Cysber Phaden II e Ser II o Lrg Cly Lysda Clalys Clutyrdle Phetyr Lysleuder II e II e Pro II e de pasaden protentraleu Atadadal cototitica a tatacaca tadas cotadas cocadas atatica titta tadada tataca tada tada a tada a tada a tada CysVallysLeuThrProLeuCysVal SerLeuLysCysThrAspLeuGlyAsaAlaThrAsaThrAsaSerSerAsaThrAsaSerSerSerSerGlyGluHetMetGluLysGlyGlu tetetalattalececletetetetetaligtecacteatttecegaatectactaataccaatactaataccaataccaatagtacceccaatacateateatecacac Thr Ber Cys Lanthr Ber Val II athr Cladla Cyelrolys Val Ber Phe Glufro II effet is Tyr Cys Alafro Ala Glyfhe Ala II elaulys Cys Landen Lys Thr Phe acalottotalcacotcactalcacaegegi etgeliliggiatectttgagegaatteccatacattattotgegegegegittigegaittelalalalatalgagette 6200

0079

Tyrtyrglyval Proval trpLyagludla Thr Thr Thr Laubhagyakla Sarkapkla Lyakla Tyrka pThr Gluval Hiakanyal Trpkla Thr Hiaklaval Proval Prova Tros Tros Sarka Sar

2000

The Trppheden Ser The Trp Ser The Glugly Ser denden The Glugly Ser dep The Ile The Leu Pro Cyeder Ile Lye Glaphelle den Hetrp Glaglu Vel Gly Lye Ale AepMetArgAepAenTrpArgGerGluLeuTyrLyeTyrLyeVelValLyeIleGluProLeuGlyVelAlæProThrLyeAleLyeArgArgVelVelGluArgGluLyeArgAleVel <u>Aendiythrölyprocyethräenvalberthrvaldingyethrbladiytleaprovalvalberthrölmlaulaulaukanglyberlauda agluglugluvalvaltlakka</u> Aatogaalaaggacatotagaaatogaagaagaagaagatotagaattaggcaagtagtattaatotaaactoaacatgaatggcaggaagaagagagaataattaga leral e denthe Thraspaenta Lyothe Holleval Cluleuden Clulleden Cyathe Argeroden den den the Argeye Ber Hedre He Glude gely Pro acttectttaatactacttegaetactelaategctelaacctgaacgaactgaccactccccteccatecacattaaacaatttataaacatetecceggaagtaggaa 6200 6900 7000

GIYILeTrpGIYCYelerGIYLYeLeuIleCyeThrThrAleValProTrpAeaAleferTrpSerAeaLyeSerLeuGluGlaIleTrpAeaAeaKetThrTrpHetGluTrpAepArg GIYII. GIYAI aLaufbe LauGIYfba LauGIYAI aAl aGIYfar Thr Hat GIYAI aArgfar Mat Thr Lau Thr Wal Glad I aArgGla Lau Laufar GIYII aVal Gla Gla Gladan galat localcottectecottotteccalcalcalcalcalcalteteccaccacalcatal calcatal acadalalacalcalal estectecotal and to Asolouloudradialicciudicciocionioleucioleucioleumrya, Trpciy Ilalyacioleuciodialargii eleudiavai ciudregyrleulyadepciocioleuleu AATTICCTCLG GGCTATTGAG GCGCLACAGCA TCTGTTGCAACTCACA GTGTGGGGCA TCAAGGCTGCA GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGGTCCTG

ClulledendenTyrThrBerLaulleBleSerLaulleGluGluBerCladenGlaGlaLysdenGluGlaGluLauLeuGluLeudepLyeTrpdleSerLauTrpden

ب ف

gala tillcaattilcacaaccitalilca ticctilaticgcaaaccecaagaaccacaagaacaacaacaacaacaattatiggaattaatggccaagttiggcaatt

Asallothraaltractortratalalyollothollowallavalclyclyclouvalclycautellovalthoalavallouborllovaldoadegvaldegclaclyfyebor Aacatalaltractortratalaatattrataltacatactacaccettgctaccittalcataltittectgtattitatatactgaatacactaeccaccatattea

AlaLoulieTrpAepAspLeuArgsarLouCysLouPheSerTyrHieArgLouArgAspLouLouLoulauileValThrArgIIeValGluLouLouGlyArgArgGlyTrpGluAlaLou

aaatattootogaatotootalatattoga opeactaaacaataaaatalootototagotogatoolatooca eccatagca opegotogoga catagotatata Lystyrtrytrytanlaulauchatyrtryberchachulysdenberdievel berlaulaudendiethral alladiaveldlachuchyphrdephrevel Hochwalval 8100

gcactiatctgcalcatctgcgacctgtgcgtgtacactacacctroacactaccttactgttattctatalcaacattactct

GlnGlyAlaCysArgAlaIlaArgHisIlaProArgArgIlaArgGlnGlyLauGluArgIlaLauLau . 6100

ORF F - AspargalatrplysclyPhacystyrly MayclyclystrpBarlysbarBarvalValClytrpFroThrVal Caagecttotagacctattcccaalactagaalaaataacacaccettccaaaattaccaacettccaaac

TrpLeuGluklaGluGluGluGluGluValGlythaFroValThrFroGlaValFroLeuArgFroHatThrTyrLgaAlaAlaValAapLauBarHlaPhaLauLyaGluLyaGlyGly 009

LeuthrPhedlyTrpCysTyrLysLeuValProValGluProAspLysValGluGluAlsAsnLysGlyGluAsnThrSerLeuLeuWlsProValSerLeuHisGlyMerAspAspPro

GluargGluValLeuGluTrpArgTheAspSerArgLeuAlaPheHisHisHisHlaArgGluUeuHisProGluTyrPhaLysAsnGya 9800

COCTCCCCLCTTCCAGCCAGOCCTGCCCTGCCGGCACTGGCGALGTGCCGAGGCGTCACATGCTGCATATAACAGCTGCTTTTTGGCTGTAGTGGGTGTGTGGGTTAGAGCAGATTT

INTERNATIONAL SEARCH REPORT

		International Application No PCT	/EP 86/00018	
I. CLASSIFICATION F SUBJECT MATTER (if several classification symbols apply, indicate all) *				
Accordin	ng to International Patent Classification (IPC) or to both N	iational Classification and IPC		
IPC4:	C 07 K 15/00; C 12 P 21/0	00; C 12 N 5/00; G 0	1 N 33/569;	
	G 01 N 33/577; C 07 K 3/1	8 // C 12 N 15/00	./.	
II. FIELD	S SEARCHED			
	Minimum Docurr	sentation Searched ?	······································	
Classificat	tion System	Classification Symbols		
4	C 12 P			
IPC	A 61 K			
I	j G 01 N			
	Page imposation Coscolad at la			
		r than Minimum Documentation its are included in the Fields Searched *		
				
		•		
III. DOC	UMENTS CONSIDERED TO BE RELEVANT		· · · · · · · · · · · · · · · · · · ·	
Category *		ppropriate, of the relevant passages 12	Relevant to Claim No. 13	
			i	
X,P	EP, A, 0138667 (INSTITUT	PASTEUR) 24 April	•	
	1985, see page 7, lin	e 34 - page 8, line	1,4,7,8	
	17; page 9, lines 6-1	1,18-25; page 10,		
	lines 23-32; page 11,	line 11 - page 12,	•	
	line 7; page 23, line	s 13-21 and line	j	
	29 - page 24, line 5;	claims 1.5-7		
X,P	Proc. Natl. Acad. Sci. US	A, volume 82.		
	August 1985		•	
	F. Di Marzo Veronese	et al.: "Monoclonal		
	antibodies specific fo	or p24, the major		
	core protein of human	T-cell leukemia		
	virus type III", page:	s 5199-5202		
	see page 5199, left-ha	and column lines	1 1 7 0	
	11-16; right-hand colu	umn lines 0-12.	1,4,7,8	
	page 5200, left-hand	column lines 3-13;		
	right-hand column, lim	ne 10 - page 5201		
	left-hand column line	ne 10 - page 5201,		
	<pre>left-hand column, line left-hand column, line</pre>	= 1; page 5201,		
	rere nand cordini, iin	25 0-10,23-30	•	
X.P	Biological Abstracts/Revie	aws Penorts		
,-	Meetings, 1985	ews, Reports,		
	F.V. Dimarzo et al.:"N	Monoclonal anti-	.1	
<u>.</u>			./.	
Special categories of cited documents: 10 "T" later document published after the international filling date.				
"A" doc	ument defining the general state of the art which is not sidered to be of particular relevance	or priority date and not in conflic cited to understand the principle	t with the application but	
	ier document but published on or after the international	IUAGUIIOU		
TILLE	g date	"X" document of particular relevance cannot be considered noval or	s; the claimed invention cannot be considered to	
Will	ument which may throw doubts on priority claim(s) or th is cited to establish the publication date of another	Involve an inventive step		
Citation or other special reason (as specified) Cannot be considered to involve an inventive step when the				
other means, such combined with one or more other such docu-				
"P" document published prior to the international filing date but later than the priority date claimed "A" document member of the same patent family				
IV. CERTIFICATION				
Date of the Actual Completion of the International Search Date of Mailing of this International Search Report				
15th April 1986 2 2 MAI 1986			•	
<u> </u>				
International Searching Authority Signature of Authorized Office				
EUROPEAN PATENT OFFICE M. VAN MOL				

I. CLASSIFICATION_OF SUBJECT MATTER (if several classification symbols apply, Indicate all) 6				
According to International Patent Classification (IPC) or to both National Classification and IPC				
IPC4:	(C 12 P 21/00; C 12 R 1:	91)		
		·		
II. PIEL	DS SEARCHED			
Clausifica	tion System	umentation Searched 7 Classification Symbols		
		Classification Symbols		
IPC4			,	
	Documentation Searched of	ner than Minimum Documentation		
		ents are included in the Fields Searched *		
			· · · · · · · · · · · · · · · · · · ·	
	·		•	
III. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of Document, 11 with Indication, where	appropriate, of the relevant passages 12	Relevant to Claim No. 13	
	bodies specific to hum	an T cell leukemia		
	virus III gag proteins		1-8	
	terms			
		-		
A	Science, volume 225, 6 Jul	y 1984 .		
	P.M. Feorino et al.:"I associated virus infec			
	donor-recipient pair w			
	deficiency syndrome",	pages 69-72.		
	see page 69, abstract,		1,4	
	left-hand column, line			
	column, lines 6-10; pa			
	column lines 6-11,23-2	6; right-hand		
	column, lines 34-54; p	age 72, left-hand	·	
	column, lines 9-14	_		
A	Journal of Experimental Me	dicine, volume 159.		
**	April 1984	, verame,	·	
Ì	T.J. Palker et al.: "Mo	noclonal antibodies		
	against human T cell l			
į	virus (HTLV) p24 inter			
ľ	pages 1117-1131, see p	age 1117, lines 4-	1-9	
ļ	12,16-18; page 1118, li lines 25-28,31-35	nes 3-11; page 1129,		
* Special categories of cited documents: 19 The later document published after the international filing date				
CON	iment defining the general state of the art which is not lidered to be of particular relevance	or priority date and not in conflict cited to understand the principle		
"E" earle	er document but published on or after the international plate.	invention "X" document of particular relevance	: the claimed invention	
"L" document which may throw doubts on priority claim(s) or				
Citat	h is cited to establish the publication date of another ion or other special reason (as specified)	"Y" document of particular relevance		
*O" document referring to an oral disclosure, use, exhibition or other means Cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled				
occument published prior to the international filing date but in the art.				
"A" document member of the same patent family IV. CERTIFICATION				
Date of the Actual Completion of the Island				
15th April 1986				
Internationa	International Searching Authority Signature of Authorized Officer			
	EUROPEAN PATENT OFFICE			
		1		

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/EP 86/00018 (SA 11930)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/05/86

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0138667	24/04/85	AU-A- 3307884 JP-A- 60067859	21/03/85 18/04/85